Skip to main content

Medikamentöse Therapie bei metastasierten neuroendokrinen Tumoren des gastroenteropankreatischen Systems

Medicinal therapy of metastasized neuroendocrine tumors of the gastroenteropancreatic system

Der Internist volume 53, pages 167–176 (2012)Cite this article

Zusammenfassung

Neuroendokrine Neoplasien des gastroenteropankreatischen Systems werden nach der WHO-Klassifikation 2010 in neuroendokrine Tumoren (NET) und neuroendokrine Karzinome (NEC) unterteilt. Im klinischen Alltag spielt bei NET das Grading mithilfe des Ki-67-Proliferationsindex zur Prognoseabschätzung und Therapieplanung eine essenzielle Rolle. Zudem differieren die Tumorbiologie sowie die Therapieoptionen bei NET je nach Primariuslokalisation. Die palliative Therapie bei inoperablen NET umfasst lokal-ablative Maßnahmen bei ausschließlicher Lebermetastasierung, die peptidrezeptorvermittelte Radiotherapie (PRRT) bei Tumoren, die Somatostatinrezeptoren exprimieren, und verschiedene medikamentöse Therapieoptionen. In diesem Beitrag wird der aktuelle Stellenwert der Biotherapie mit Somatostatinanaloga und Interferon-α in der Symptom- und Tumorkontrolle beschrieben. Zudem werden die konventionelle Chemotherapie und neu zugelassene molekular zielgerichtete Therapieansätze mit Sunitinib und Everolimus bei NET des Pankreas dargestellt. Mögliche Therapiealgorithmen werden diskutiert.

Abstract

Neuroendocrine neoplasms of the gastroenteropancreatic system are classified according to the WHO classification system 2010 into neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC). The proliferation index Ki-67 and the grading of NETs is essential for the prognosis and therapy plan. Also NET tumor biology and therapeutic options may differ depending on the primary NET tumor location. Palliative therapy of inoperable NETs involves local ablative methods in cases of primary liver metastasis, peptide receptor radionuclide therapy (PRRT) in NETs expressing somatostatin receptors and different options for medicinal therapy. This manuscript reviews the current role of biotherapy with somatostatin analogues and interferon-alpha for symptom and tumor control. In addition conventional chemotherapy regimens and novel molecular targeted therapeutic options, such as sunitinib or everolimus in NET of the pancreas are reviewed. Possible therapeutic algorithms are discussed.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Abb. 1
Abb. 1

Literatur

  1. Auernhammer CJ, Göke B (2011) Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 60:1009–1021

    PubMed  Article  CAS  Google Scholar 

  2. Modlin IM, Pavel M, Kidd M, Gustafsson BI (2010) Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 31:169–188

    PubMed  CAS  Google Scholar 

  3. Plöckinger U, Wiedenmann B (2007) Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab 21:145–162

    PubMed  Article  Google Scholar 

  4. Strosberg J, Kvols L (2010) Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 16:2963–7290

    PubMed  Article  CAS  Google Scholar 

  5. Rinke A, Müller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663

    Google Scholar 

  6. National Comprehensive Cancer Network (NCCN) (2011) Guidelines. http://www.nccn.org

  7. North American Neuroendocrine Tumor Society (NANETS) (2010) Guidelines. http://nanets.net

  8. Faiss S, Pape UF, Böhmig M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689–2696

    Google Scholar 

  9. European Neuroendocrine Tumor Society (ENETS) (2009) Guidelines and standards of care. http://www.enets.org/

  10. Pavel ME, Baum U, Hahn EG et al (2006) Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 26:8–13

    Google Scholar 

  11. Fazio N, Braud F de, Delle Fave G, Oberg K (2007) Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol 18:13–19

    PubMed  Article  CAS  Google Scholar 

  12. Moertel CG, Lefkopoulo M, Lipsitz S et al (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523

    Google Scholar 

  13. Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198

    Google Scholar 

  14. Ramanathan RK, Cnaan A, Hahn RG et al (2001) Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 12:1139–1143

    PubMed  Article  CAS  Google Scholar 

  15. Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:268–275

    PubMed  Article  CAS  Google Scholar 

  16. Bajetta E, Catena L, Procopio G et al (2007) Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59:637–642

    PubMed  Article  CAS  Google Scholar 

  17. Maire F, Hammel P, Kianmanesh R et al (2009) Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery 145:69–75

    PubMed  Article  Google Scholar 

  18. Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227–232

    PubMed  Article  CAS  Google Scholar 

  19. Mitry E, Baudin E, Ducreux M et al (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351–1355

    PubMed  Article  CAS  Google Scholar 

  20. Hainsworth JD, Spigel DR, Litchy S, Greco FA (2006) Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 24:3548–3554

    Google Scholar 

  21. Deutschbein T, Unger N, Yuece A et al (2011) Chemotherapy in patients with progressive, undifferentiated neuroendocrine tumors: a single-center experience. Horm Metab Res 43:838–843

    PubMed  Article  CAS  Google Scholar 

  22. Welin S, Sorbye H, Sebjornsen S et al (2011) Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer (im Druck)

  23. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523

    Google Scholar 

  24. Yao JC, Pavel M, Phan AT et al (2011) Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 96:3741–3749

    Google Scholar 

  25. Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2012

    PubMed  Article  CAS  Google Scholar 

  26. Dong M, Yao JC (2011) mTOR inhibition, a potential novel approach for bronchial carcinoids. Endocr Relat Cancer 18:C15–C18

    PubMed  Article  CAS  Google Scholar 

  27. Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513. Erratum in: N Engl J Med 364:1082

    Google Scholar 

  28. Jensen RT, Delle Fave G (2011) Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 364:564–565

    Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: C.J. Auernhammer hat in Zusammenhang mit dem Thema „neuroendokrine Tumoren“ Forschungsgelder (Ipsen, Novartis) sowie Honorare für Vortragstätigkeiten (Ipsen, Novartis, Pfizer, Roche, Falk Foundation) und Tätigkeiten in wissenschaftlichen Beiräten (Ipsen, Novartis) erhalten.

C. Spitzweg hat in Zusammenhang mit dem Thema „neuroendokrine Tumoren“ Forschungsgelder (Novartis) sowie Honorare für Vortragstätigkeiten (Ipsen, Novartis) und Tätigkeiten in wissenschaftlichen Beiräten (Novartis) erhalten.

Author information

Affiliations

  1. Medizinische Klinik II, Campus Großhadern, Klinikum der Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377, München, Deutschland

    C.J. Auernhammer, C. Spitzweg & B. Göke

  2. Interdisziplinäres Zentrum für Neuroendokrine Tumoren des Gastroenteropankreatischen Systems (GEPNET-KUM), Klinikum der Ludwig-Maximilians-Universität München, München, Deutschland

    C.J. Auernhammer, C. Spitzweg, V. Heinemann & B. Göke

  3. Medizinische Klinik III, Campus Großhadern, Klinikum der Ludwig-Maximilians-Universität München, München, Deutschland

    V. Heinemann

Authors
  1. C.J. Auernhammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Spitzweg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Heinemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Göke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C.J. Auernhammer.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Auernhammer, C., Spitzweg, C., Heinemann, V. et al. Medikamentöse Therapie bei metastasierten neuroendokrinen Tumoren des gastroenteropankreatischen Systems. Internist 53, 167–176 (2012). https://doi.org/10.1007/s00108-011-2919-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-011-2919-z

Schlüsselwörter

  • Neuroendokrine Tumoren
  • Somatostatinanaloga
  • Chemotherapie
  • Sunitinib
  • Everolimus

Keywords

  • Neuroendocrine tumors
  • Somatostatin analogues
  • Chemotherapy
  • Sunitinib
  • Everolimus